3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Glioma
4
Thyroid Neoplasms
3
Sarcoma
3
Central Nervous System Neoplasms
3
Wilms Tumor
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Neoplasms
2
Multiple Myeloma
2
Melanoma
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lung Neoplasms
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Ependymoma
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Xanthogranuloma, Juvenile
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Solid Tumors Harboring NTRK Fusion
1
Sarcoma, Ewing
1
Interventions
Gemcitabine
32
Cisplatin
31
durvalumab
15
pembrolizumab
14
Fluorouracil
13
Oxaliplatin
12
Leucovorin
12
Capecitabine
10
Bevacizumab
8
lenvatinib
7
Nivolumab
7
zanidatamab
4
Trastuzumab
4
S 1 (combination)
4
Paclitaxel
4
Liquid Biopsy
4
Irinotecan
4
Carboplatin
4
Albumin-Bound Paclitaxel
4
tremelimumab
3
tislelizumab
3
irinotecan sucrosofate
3
Injections
3
Folfox protocol
3
130-nm albumin-bound paclitaxel
3
toripalimab
2
pertuzumab
2
niraparib
2
ivosidenib
2
envafolimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
larotrectinib
×
1 year
×
Clear all
NCT02576431
2026-04-28
NAVIGATE
Bayer
Phase 2
Completed
215 enrolled
2 FDA